Gene: Pygl (glycogen phosphorylase L) Rattus norvegicus
Analyze
Symbol:
Pygl
Name:
glycogen phosphorylase L
CRRD ID:
620687
Description:
Exhibits carbohydrate binding activity; glycogen phosphorylase activity; and identical protein binding activity. Involved in 5-phosphoribose 1-diphosphate biosynthetic process and glycogen catabolic process. Localizes to cytoplasm. Used to study glycogen storage disease VI and lactic acidosis. Human ortholog(s) of this gene implicated in glycogen storage disease; glycogen storage disease VI; and lactic acidosis. Orthologous to human PYGL (glycogen phosphorylase L); PARTICIPATES IN glycogen degradation pathway; glycogen metabolic pathway; congenital sucrase-isomaltase deficiency pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 17alpha-ethynylestradiol; 17beta-estradiol.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
glycogen phosphorylase; glycogen phosphorylase, liver form; liver glycogen phosphorylase; phosphorylase, glycogen, liver
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
PYGL (glycogen phosphorylase L) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, PhylomeDB, Treefam
Mus musculus (house mouse):
Pygl (liver glycogen phosphorylase) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Pygl (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
PYGL (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
PYGL (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Pygl (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
PYGL (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Chlorocebus sabaeus (African green monkey):
PYGL (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Heterocephalus glaber (naked mole-rat):
Pygl (glycogen phosphorylase L) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Other homologs 2
Homo sapiens (human):
PYGB (glycogen phosphorylase B) HGNC
OrthoMCL
Homo sapiens (human):
PYGM (glycogen phosphorylase, muscle associated) HGNC
OrthoMCL
Alliance orthologs 3
Homo sapiens (human):
PYGL (glycogen phosphorylase L)
Alliance
DIOPT (Ensembl Compara|HGNC|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Mus musculus (house mouse):
Pygl (liver glycogen phosphorylase)
Alliance
DIOPT (Ensembl Compara|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Danio rerio (zebrafish):
pygl (phosphorylase, glycogen, liver)
Alliance
DIOPT (PhylomeDB|TreeFam)
Saccharomyces cerevisiae (baker's yeast):
GPH1
Alliance
DIOPT (Ensembl Compara|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Drosophila melanogaster (fruit fly):
GlyP
Alliance
DIOPT (Ensembl Compara|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PhylomeDB|TreeFam)
Caenorhabditis elegans (roundworm):
pygl-1
Alliance
DIOPT (Ensembl Compara|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PhylomeDB|TreeFam)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 6 92,597,759 - 92,643,734 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 6 92,597,706 - 92,643,847 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 6 102,045,144 - 102,091,119 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 6 92,298,339 - 92,341,347 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 6 92,301,796 - 92,344,803 (-) NCBI Celera 6 87,191,869 - 87,228,313 (-) NCBI Celera Cytogenetic Map 6 q24 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Annotations - ClinVar
Developmental Disabilities ISO RGD:731803 8554872 ClinVar Annotator: match by term: Global developmental delay ClinVar PMID:30311386 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:25741868 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:12809646 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:21646031 more ... glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:25266922 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:22899091 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:17705025 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:17705025 , PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:21646031 more ... glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:24033266 , PMID:25741868 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:25741868 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:28492532 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar PMID:9536091 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar PMID:9529348 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar PMID:24033266 glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by OMIM:232700 ClinVar glycogen storage disease VI ISO RGD:731803 8554872 ClinVar Annotator: match by term: Glycogen storage disease, type VI ClinVar PMID:17705025 , PMID:25741868
Imported Annotations - CTD
Chemical and Drug Induced Liver Injury ISO RGD:731803 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:25231249 glycogen storage disease VI ISO RGD:731803 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:9529348 , PMID:9536091 hepatocellular carcinoma ISO RGD:731803 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:2885971 Imported Annotations - OMIM
glycogen storage disease VI ISO RGD:731803 7240710 OMIM
1,1-dichloroethene decreases expression ISO RGD:731804 6480464 vinylidene chloride results in decreased expression of PYGL mRNA CTD PMID:26682919 1,2-dichloroethane decreases expression ISO RGD:731804 6480464 ethylene dichloride results in decreased expression of PYGL mRNA, ethylene dichloride results in decreased expression of PYGL protein CTD PMID:28189721 , PMID:28960355 1,2-dimethylhydrazine decreases expression ISO RGD:731804 6480464 1, 2-Dimethylhydrazine results in decreased expression of PYGL mRNA CTD PMID:22206623 1-naphthyl isothiocyanate decreases expression EXP 6480464 1-Naphthylisothiocyanate results in decreased expression of PYGL mRNA CTD PMID:17522070 17alpha-ethynylestradiol multiple interactions ISO RGD:731804 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PYGL mRNA CTD PMID:17942748 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of PYGL mRNA CTD PMID:17557909 17beta-estradiol decreases expression ISO RGD:731804 6480464 Estradiol results in decreased expression of PYGL mRNA CTD PMID:19484750 17beta-estradiol multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of PYGL mRNA CTD PMID:26496021 1H-pyrazole decreases expression ISO RGD:731804 6480464 pyrazole results in decreased expression of PYGL mRNA CTD PMID:17945193 2,3',4,4',5-Pentachlorobiphenyl increases expression ISO RGD:731804 6480464 2 more ... CTD PMID:31388691 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:731804 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PYGL mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:731804 6480464 Tetrachlorodibenzodioxin results in decreased expression of PYGL mRNA CTD PMID:19770486 , PMID:27562557 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:731803 6480464 Tetrachlorodibenzodioxin results in increased expression of PYGL mRNA CTD PMID:22903824 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of PYGL mRNA CTD PMID:20959002 , PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:731804 6480464 Tetrachlorodibenzodioxin affects the expression of PYGL mRNA CTD PMID:21570461 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of PYGL mRNA CTD PMID:21346803 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of PYGL mRNA CTD PMID:21346803 2-hydroxypropanoic acid decreases expression ISO RGD:731803 6480464 Lactic Acid results in decreased expression of PYGL mRNA CTD PMID:30851411 3,3',4,4',5-pentachlorobiphenyl decreases expression EXP 6480464 3 more ... CTD PMID:27509375 , PMID:29474705 3-chloropropane-1,2-diol increases expression EXP 6480464 alpha-Chlorohydrin results in increased expression of PYGL protein CTD PMID:26597043 3H-1,2-dithiole-3-thione decreases expression EXP 6480464 1, 2-dithiol-3-thione results in decreased expression of PYGL mRNA CTD PMID:19162173 4'-hydroxyacetophenone affects binding EXP 6480464 4-hydroxyacetophenone binds to PYGL protein CTD PMID:15236443 4,4'-diaminodiphenylmethane increases expression ISO RGD:731804 6480464 4, 4'-diaminodiphenylmethane results in increased expression of PYGL mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol increases expression ISO RGD:731804 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of PYGL mRNA CTD PMID:30951980 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole affects expression EXP 6480464 Omeprazole affects the expression of PYGL mRNA CTD PMID:19483382 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of PYGL mRNA CTD PMID:19483382 8-Br-cAMP decreases expression ISO RGD:731803 6480464 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PYGL mRNA CTD PMID:22079614 acetylsalicylic acid affects binding EXP 6480464 Aspirin binds to PYGL protein CTD PMID:15236443 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of PYGL mRNA CTD PMID:31644924 acrylamides affects binding ISO RGD:731803 6480464 Acrylamides analog binds to PYGL protein CTD PMID:18723356 acrylamides decreases activity ISO RGD:731803 6480464 Acrylamides analog results in decreased activity of PYGL protein CTD PMID:18723356 aldehydo-D-glucose multiple interactions EXP 6480464 Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 aluminium phosphide increases activity EXP 6480464 aluminum phosphide results in increased activity of PYGL protein CTD PMID:20929055 alvocidib affects binding ISO RGD:731803 6480464 PYGL protein binds to alvocidib CTD PMID:11368340 amiodarone affects expression EXP 6480464 Amiodarone affects the expression of PYGL mRNA CTD PMID:19483382 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of PYGL mRNA CTD PMID:16483693 arsenite(3-) multiple interactions ISO RGD:731804 6480464 arsenite inhibits the reaction [INS protein results in decreased activity of PYGL protein] CTD PMID:28952001 arsenous acid increases expression ISO RGD:731803 6480464 Arsenic Trioxide results in increased expression of PYGL mRNA CTD PMID:20458559 atrazine increases expression ISO RGD:731803 6480464 Atrazine results in increased expression of PYGL mRNA CTD PMID:22378314 benzamide decreases activity ISO RGD:731803 6480464 benzamide analog results in decreased activity of PYGL protein CTD PMID:19758809 benzbromarone affects expression EXP 6480464 Benzbromarone affects the expression of PYGL mRNA CTD PMID:19483382 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of PYGL mRNA CTD PMID:21839799 benzo[a]pyrene affects methylation ISO RGD:731803 6480464 Benzo(a)pyrene affects the methylation of PYGL promoter CTD PMID:27901495 benzo[a]pyrene decreases expression ISO RGD:731804 6480464 Benzo(a)pyrene results in decreased expression of PYGL mRNA CTD PMID:22228805 bis(2-ethylhexyl) phthalate multiple interactions EXP 6480464 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of PYGL promoter CTD PMID:23359474 bis(2-ethylhexyl) phthalate increases expression ISO RGD:731803 6480464 Diethylhexyl Phthalate results in increased expression of PYGL mRNA CTD PMID:31163220 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of PYGL promoter, [bisphenol A co-treated with Estradiol] results in increased expression of PYGL mRNA CTD PMID:23359474 , PMID:26496021 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of PYGL mRNA CTD PMID:30816183 bisphenol A increases expression ISO RGD:731804 6480464 bisphenol A results in increased expression of PYGL mRNA CTD PMID:30951980 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of PYGL mRNA CTD PMID:25181051 bisphenol F increases expression ISO RGD:731804 6480464 bisphenol F results in increased expression of PYGL mRNA CTD PMID:30951980 buspirone decreases expression EXP 6480464 Buspirone results in decreased expression of PYGL mRNA CTD PMID:24136188 cadmium dichloride increases expression ISO RGD:731803 6480464 Cadmium Chloride results in increased expression of PYGL mRNA CTD PMID:26472689 Calcimycin increases activity EXP 6480464 Calcimycin results in increased activity of PYGL protein CTD PMID:6430282 Calcimycin multiple interactions EXP 6480464 Calcium deficiency inhibits the reaction [Calcimycin results in increased activity of PYGL protein] CTD PMID:6430282 calcium atom multiple interactions EXP 6480464 [Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein more ... CTD PMID:6430282 , PMID:747652 calcium(0) multiple interactions EXP 6480464 [Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein more ... CTD PMID:6430282 , PMID:747652 carbon nanotube decreases expression ISO RGD:731804 6480464 Nanotubes, Carbon analog results in decreased expression of PYGL mRNA, Nanotubes, Carbon results in decreased expression of PYGL mRNA CTD PMID:25620056 chloroacetaldehyde affects expression ISO RGD:731803 6480464 chloroacetaldehyde affects the expression of PYGL mRNA CTD PMID:25596134 chloroacetic acid decreases expression ISO RGD:731804 6480464 chloroacetic acid results in decreased expression of PYGL mRNA, chloroacetic acid results in decreased expression of PYGL protein CTD PMID:28189721 chloroform decreases expression EXP 6480464 Chloroform results in decreased expression of PYGL mRNA CTD PMID:17522070 chloropicrin decreases expression ISO RGD:731803 6480464 chloropicrin results in decreased expression of PYGL mRNA CTD PMID:28476498 chloropicrin increases expression ISO RGD:731803 6480464 chloropicrin results in increased expression of PYGL mRNA CTD PMID:26352163 ciguatoxin CTX1B affects expression ISO RGD:731804 6480464 Ciguatoxins affects the expression of PYGL mRNA CTD PMID:18353800 cisplatin decreases expression ISO RGD:731803 6480464 Cisplatin results in decreased expression of PYGL mRNA CTD PMID:25596134 cisplatin increases expression ISO RGD:731803 6480464 Cisplatin results in increased expression of PYGL mRNA CTD PMID:27392435 , PMID:27594783 clofibrate affects expression EXP 6480464 Clofibrate affects the expression of PYGL mRNA CTD PMID:19483382 clofibrate decreases expression EXP 6480464 Clofibrate results in decreased expression of PYGL protein CTD PMID:16470657 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of PYGL mRNA CTD PMID:24386269 copper(II) sulfate decreases expression ISO RGD:731803 6480464 Copper Sulfate results in decreased expression of PYGL mRNA CTD PMID:19549813 cyclosporin A decreases expression ISO RGD:731804 6480464 Cyclosporine results in decreased expression of PYGL mRNA CTD PMID:19770486 cyclosporin A decreases expression EXP 6480464 Cyclosporine results in decreased expression of PYGL mRNA CTD PMID:25596134 cyclosporin A decreases expression ISO RGD:731803 6480464 Cyclosporine results in decreased expression of PYGL mRNA CTD PMID:25562108 , PMID:25596134 D-glucose multiple interactions EXP 6480464 Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 dexamethasone increases expression ISO RGD:731803 6480464 Dexamethasone results in increased expression of PYGL mRNA CTD PMID:25047013 diarsenic trioxide increases expression ISO RGD:731803 6480464 Arsenic Trioxide results in increased expression of PYGL mRNA CTD PMID:20458559 dibutyl phthalate multiple interactions EXP 6480464 [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of PYGL promoter CTD PMID:23359474 dichlorvos increases activity EXP 6480464 Dichlorvos results in increased activity of PYGL protein CTD PMID:222008 dioxygen increases expression ISO RGD:731804 6480464 Oxygen deficiency results in increased expression of PYGL mRNA CTD PMID:20880076 dioxygen increases expression ISO RGD:731803 6480464 Oxygen deficiency results in increased expression of PYGL mRNA CTD PMID:25596134 dorsomorphin multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin increases expression ISO RGD:731803 6480464 Doxorubicin results in increased expression of PYGL mRNA CTD PMID:30031762 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of PYGL mRNA CTD PMID:29391264 entinostat increases expression ISO RGD:731803 6480464 entinostat results in increased expression of PYGL mRNA CTD PMID:27188386 erythromycin estolate decreases expression EXP 6480464 Erythromycin Estolate results in decreased expression of PYGL mRNA CTD PMID:17522070 fenofibrate increases expression EXP 6480464 Fenofibrate results in increased expression of PYGL mRNA CTD PMID:25596134 Geniposide increases expression EXP 21079733 Geniposide increased expression of PYGL in serum RGD glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of PYGL mRNA CTD PMID:24136188 glucose multiple interactions EXP 6480464 Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 ibuprofen increases expression EXP 6480464 Ibuprofen results in increased expression of PYGL mRNA CTD PMID:25596134 ifosfamide decreases expression ISO RGD:731803 6480464 Ifosfamide results in decreased expression of PYGL mRNA CTD PMID:25596134 isoprenaline increases activity EXP 6480464 Isoproterenol results in increased activity of PYGL protein CTD PMID:6430282 L-ethionine affects expression EXP 6480464 Ethionine affects the expression of PYGL mRNA CTD PMID:19483382 malathion multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Malathion results in increased expression of PYGL mRNA] CTD PMID:25449180 malathion increases expression EXP 6480464 Malathion results in increased expression of PYGL mRNA CTD PMID:25449180 metformin decreases expression EXP 6480464 Metformin results in decreased expression of PYGL mRNA CTD PMID:25596134 methylarsonite multiple interactions ISO RGD:731804 6480464 methylarsonite inhibits the reaction [INS protein results in decreased activity of PYGL protein] CTD PMID:28952001 methylmercury chloride decreases expression ISO RGD:731803 6480464 methylmercuric chloride results in decreased expression of PYGL mRNA CTD PMID:23179753 , PMID:27188386 N-acetyl-L-cysteine multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Malathion results in increased expression of PYGL mRNA] CTD PMID:25449180 N-nitrosomorpholine decreases expression EXP 6480464 N-nitrosomorpholine results in decreased expression of PYGL protein CTD PMID:2885971 N-nitrosomorpholine affects expression EXP 6480464 N-nitrosomorpholine affects the expression of PYGL protein CTD PMID:19716841 nefazodone decreases expression EXP 6480464 nefazodone results in decreased expression of PYGL mRNA CTD PMID:24136188 neostigmine increases activity EXP 6480464 Neostigmine results in increased activity of PYGL protein modified form CTD PMID:1350317 neostigmine multiple interactions EXP 6480464 Phentolamine inhibits the reaction [Neostigmine results in increased activity of PYGL protein modified form] CTD PMID:1350317 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of PYGL mRNA CTD PMID:22110744 nicotinamide multiple interactions EXP 6480464 [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein, resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 nimesulide decreases expression EXP 6480464 nimesulide results in decreased expression of PYGL mRNA CTD PMID:24136188 omeprazole affects expression EXP 6480464 Omeprazole affects the expression of PYGL mRNA CTD PMID:19483382 paracetamol affects expression ISO RGD:731804 6480464 Acetaminophen affects the expression of PYGL mRNA CTD PMID:17562736 paracetamol multiple interactions ISO RGD:731804 6480464 PANX1 gene mutant form inhibits the reaction [Acetaminophen results in decreased expression of PYGL mRNA] CTD PMID:29246445 paracetamol decreases expression ISO RGD:731804 6480464 Acetaminophen results in decreased expression of PYGL mRNA CTD PMID:29246445 paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of PYGL mRNA CTD PMID:17522070 paracetamol multiple interactions ISO RGD:731803 6480464 [Dietary Carbohydrates co-treated with Acetaminophen] results in increased expression of PYGL mRNA CTD PMID:17093179 perfluorooctane-1-sulfonic acid decreases expression EXP 6480464 perfluorooctane sulfonic acid results in decreased expression of PYGL mRNA CTD PMID:19162173 perfluorooctanoic acid decreases expression EXP 6480464 perfluorooctanoic acid results in decreased expression of PYGL mRNA CTD PMID:19162173 phentolamine multiple interactions EXP 6480464 Phentolamine inhibits the reaction [Neostigmine results in increased activity of PYGL protein modified form] CTD PMID:1350317 phenylephrine multiple interactions EXP 6480464 [Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein, Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] CTD PMID:747652 phenylephrine increases expression EXP 6480464 Phenylephrine results in increased expression of PYGL mRNA CTD PMID:18158353 pirinixic acid affects expression EXP 6480464 pirinixic acid affects the expression of PYGL mRNA CTD PMID:19483382 potassium chromate increases expression ISO RGD:731803 6480464 potassium chromate(VI) results in increased expression of PYGL mRNA CTD PMID:22714537 pyrogallol increases expression ISO RGD:731804 6480464 Pyrogallol results in increased expression of PYGL mRNA CTD PMID:20362636 rac-lactic acid decreases expression ISO RGD:731803 6480464 Lactic Acid results in decreased expression of PYGL mRNA CTD PMID:30851411 resveratrol multiple interactions EXP 6480464 resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of PYGL mRNA CTD PMID:28374803 rotenone increases expression ISO RGD:731803 6480464 Rotenone results in increased expression of PYGL mRNA CTD PMID:29955902 SB 431542 multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 sodium dichromate decreases expression EXP 6480464 sodium bichromate results in decreased expression of PYGL mRNA CTD PMID:25993096 streptozocin multiple interactions EXP 6480464 [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein, resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 streptozocin decreases expression EXP 6480464 Streptozocin results in decreased expression of PYGL mRNA CTD PMID:25905778 sunitinib decreases expression ISO RGD:731803 6480464 Sunitinib results in decreased expression of PYGL mRNA CTD PMID:31533062 tert-butyl hydroperoxide increases expression ISO RGD:731803 6480464 tert-Butylhydroperoxide results in increased expression of PYGL mRNA CTD PMID:15336504 Tesaglitazar increases expression EXP 6480464 tesaglitazar results in increased expression of PYGL mRNA CTD PMID:21515302 tetrachloromethane affects expression ISO RGD:731804 6480464 Carbon Tetrachloride affects the expression of PYGL mRNA CTD PMID:17484886 tetrachloromethane decreases expression ISO RGD:731804 6480464 Carbon Tetrachloride results in decreased expression of PYGL mRNA CTD PMID:27339419 , PMID:31919559 tetrachloromethane affects expression EXP 6480464 Carbon Tetrachloride affects the expression of PYGL mRNA CTD PMID:15963342 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of PYGL mRNA CTD PMID:17522070 , PMID:31150632 tetracycline decreases expression EXP 6480464 Tetracycline results in decreased expression of PYGL mRNA CTD PMID:17522070 thimerosal decreases expression ISO RGD:731803 6480464 Thimerosal results in decreased expression of PYGL mRNA CTD PMID:27188386 thioacetamide affects expression EXP 6480464 Thioacetamide affects the expression of PYGL mRNA CTD PMID:19483382 titanium dioxide increases expression ISO RGD:731804 6480464 titanium dioxide results in increased expression of PYGL mRNA CTD PMID:23409001 titanium dioxide affects expression ISO RGD:731804 6480464 titanium dioxide affects the expression of PYGL mRNA CTD PMID:17656681 titanium dioxide decreases expression ISO RGD:731804 6480464 titanium dioxide results in decreased expression of PYGL mRNA CTD PMID:23557971 trichostatin A increases expression ISO RGD:731803 6480464 trichostatin A results in increased expression of PYGL mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYGL mRNA CTD PMID:27188386 Triptolide decreases expression EXP 6480464 triptolide results in decreased expression of PYGL mRNA CTD PMID:23639586 troglitazone decreases expression EXP 6480464 troglitazone results in decreased expression of PYGL mRNA, troglitazone results in decreased expression of PYGL protein CTD PMID:21315101 , PMID:21515302 tungsten decreases expression ISO RGD:731804 6480464 Tungsten results in decreased expression of PYGL mRNA CTD PMID:30912803 valdecoxib decreases expression EXP 6480464 valdecoxib results in decreased expression of PYGL mRNA CTD PMID:24136188 valproic acid increases expression ISO RGD:731804 6480464 Valproic Acid results in increased expression of PYGL mRNA CTD PMID:21427059 valproic acid increases expression ISO RGD:731803 6480464 Valproic Acid results in increased expression of PYGL mRNA CTD PMID:19101580 more ... valproic acid multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYGL mRNA CTD PMID:27188386 valproic acid affects expression ISO RGD:731803 6480464 Valproic Acid affects the expression of PYGL mRNA CTD PMID:25979313 vorinostat multiple interactions ISO RGD:731803 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PYGL mRNA CTD PMID:27188386 vorinostat increases expression ISO RGD:731803 6480464 vorinostat results in increased expression of PYGL mRNA CTD PMID:26272509 zoledronic acid decreases expression ISO RGD:731803 6480464 zoledronic acid results in decreased expression of PYGL mRNA CTD PMID:25596134
Gene-Chemical Interaction Annotations
